How far we have come: when treatment learns from your own tumour

Picture a waiting room, fifty years ago. A family sits together, holding a diagnosis they barely understand. The doctor has done their best, but the tools are blunt. Treatment is much the same for everyone with the same type of cancer, whether it fits them or not. The question hanging in the air is not "what is the best treatment for me?" It is "is there anything at all?" Now picture that same waiting room today. The family is still anxious — that part has not changed, and it should not be minimised. But the conversation is different. The doctor can talk about the biology of this tumour, not just its name. About a test that reads the tumour's genes. About an immune system that can be taught to recognise it. About a treatment built, in one remarkable case, from the tumour itself. That is how far we have come. Not in a single leap, and not for everyone yet. But far enough that hope is no longer a platitude. It is a record. For the first time since systematic tracking began, the five-year relative survival rate for all cancers combined in the United States has reached 70%, for 2015 to 2021, up from 49% in the mid-1970s. The overall cancer death rate fell by 34% between 1991 and 2023 — an estimated 4.8 million deaths averted, according to the American Cancer Society's Cancer Statistics 2026 report.[1] Behind those numbers are people. Parents who saw a child grow up. Partners who got more years together. Patients who went back to work, to school, to ordinary life. Each one is a win we made together — researchers, nurses, pathologists, radiologists, surgeons, families, and the patients themselves who trusted a trial, asked a second question, or simply kept going. And in the last few weeks, we saw what the next chapter could look like. At the European Society for Medical Oncology Congress 2026 in Madrid, researchers presented a trial called INTerpath-001. It involved 1,137 people whose high-risk melanoma had been surgically removed, but who were at very high risk of it coming back. Half received the standard immunotherapy, pembrolizumab, alone. The other half received pembrolizumab plus intismeran — a personalised mRNA vaccine made for each person from the unique identity of their own tumour, designed to train their immune system to recognise and fight that cancer.[2] The result: adding the personalised vaccine reduced the risk of melanoma recurrence or death by 42% compared with pembrolizumab alone. For people who remained recurrence-free beyond six months, the reduction was 58%. Think about what that means, in human terms. A vaccine is not a generic drug pulled off a shelf. It is made for one person, from one tumour, to teach one immune system. It is the first mRNA cancer treatment, and the first individualised neoantigen therapy made from each patient's own cancer, to be proven in a trial of this scale — 157 sites around the world. It is still investigational. Regulatory review may take several years depending on the country, and it is not available as routine care yet. We will not pretend otherwise. But the principle has now been proven in a large, rigorous trial: treatment can learn from you, not just about you. Breast cancer tells the same story from the other direction. Sometimes winning is not a stronger drug. It is a smarter decision about who needs chemotherapy at all — and who can safely be spared it. In the phase 3 OPTIMA trial, presented at ASCO 2026, 4,429 patients aged 40 and older with ER-positive, HER2-negative early-stage breast cancer were studied. Using a gene-expression test called Prosigna to guide decisions, many patients could safely forgo chemotherapy. Five-year invasive breast cancer-free survival was 90.3% in the test-directed group, compared with 91.8% with standard treatment — and for patients with a low risk score, 93.6% and 94.8%.[3] Imagine being that patient. You have just heard the word cancer. You are bracing for months of chemotherapy. Then a test, reading the biology of your tumour, says: you do not need it. Not because anyone is cutting corners, but because the evidence says the benefit is not there for you. That is progress too — kinder, more precise, more personal. For high-risk early triple-negative breast cancer — one of the hardest forms to treat, because it does not respond to hormonal or HER2-targeted therapies — the final analysis of the KEYNOTE-522 study showed that adding pembrolizumab immunotherapy to chemotherapy before surgery, then continuing it after, continues to confer a clinically meaningful survival benefit compared with chemotherapy alone.[3] Since 2020, 17 targeted therapies have received approval or gained additional breast cancer indications. Treatment is moving away from subtype alone, toward molecularly informed, biomarker-guided care — the right treatment, for the right tumour, at the right time. We are winning together in other areas too. In metastatic melanoma, once a near-uniform death sentence with five-year survival around 16%, dual checkpoint blockade now yields 52% five-year survival. Childhood leukaemia survival has climbed from around 50% to around 89%. Kidney cancer survival has climbed from around 20% in the 1970s to around 78% today.[1] In heart failure, new 2026 guidelines now recognise treatments for people with preserved ejection fraction — a group that, until recently, had very few options — including SGLT2 inhibitors and, for some, GLP-1 therapies.[4] None of this means cancer is solved. Pancreatic cancer still has a five-year survival of around 13%. Some cancers have seen little gain. And a breakthrough presented in Madrid does not automatically reach a patient in Abuja, Lagos, or Ottawa. Progress is uneven, and access to it is uneven too. To pretend otherwise would be dishonest — and unhelpful to the people still waiting. But it does mean we are not where we were. How far we have come is not measured only in new drugs. It is measured in time — more time with family, more time to work, to plan, to live — and in clarity. Better imaging and pathology mean a diagnosis is more likely to be right the first time. Better tests mean fewer people endure treatment they do not need. Better reviews mean a second look can catch what the first missed. That is why MedSecOp exists. No treatment without clarity. Before a life-changing decision, a patient deserves the right diagnostic information, a specialist interpretation, and an understandable explanation of what it means. Hope, in this work, is not blind optimism. It is evidence, added up over fifty years, that careful science and careful diagnosis change outcomes — and that the next fifty years can change them further, if the knowledge reaches the people who need it. So if you, or someone you love, is facing a diagnosis that feels uncertain, take this with you: you are not starting from where patients started fifty years ago. You are standing on the work of millions of people who asked better questions, ran better trials, and refused to accept that this was as good as it gets. Ask for the full picture. Ask what the test does and does not rule out. Ask whether another specialist should look at the same scans, the same slides. Clarity is not doubt. It is how good decisions are made — and how we keep winning, together. MedSecOp — Clarity before critical medical decisions. Sources — verifiable: [1] American Cancer Society, Cancer Statistics 2026, via Cancer Immunotherapy 2026 summary — five-year relative survival for all cancers combined reached 70% (2015–2021), up from 49% in the mid-1970s; cancer death rate down 34% from 1991 to 2023, ~4.8 million deaths averted; melanoma, childhood leukaemia and kidney cancer survival figures. https://www.unboxfuture.com/2026/06/cancer-immunotherapy-2026-survival.html [2] Melanoma Institute Australia / ESMO Congress 2026, INTerpath-001 phase 3 trial — intismeran plus pembrolizumab reduced risk of melanoma recurrence or death by 42% vs pembrolizumab alone; 58% for patients recurrence-free beyond six months; 1,137 patients, 157 sites. https://melanoma.org.au/news/personalised-cancer-vaccine-cuts-risk-of-melanoma-recurrence/ [3] ASCO 2026, OPTIMA trial and KEYNOTE-522 final analysis — Prosigna-guided chemotherapy decisions in ER+/HER2- early breast cancer; pembrolizumab in triple-negative breast cancer; 17 targeted therapies since 2020. https://www.cancertherapyadvisor.com/indepth/new-treatments-for-early-stage-breast-cancer/ [4] Heart Failure Evidence Update 2026 and ESC 2026 Heart Failure Guidelines — SGLT2 inhibitors across ejection fraction phenotypes, GLP-1 therapies and nonsteroidal MRAs for preserved ejection fraction. https://pmc.ncbi.nlm.nih.gov/articles/PMC12979370/ Medical disclaimer: This article is for educational purposes only and does not replace professional medical advice. It describes research findings, not a recommendation for any individual patient. Discuss treatment options with your own doctor, and do not delay urgent care while seeking a second opinion.